Biopharma financing during the second quarter of 2024 totaled $22.8bn from 272 deals. Of those, 29 reached $100m or more. The venture financings category made up most (32%) of the aggregate Q2 financing dollars (see Exhibit 1).
Financing Quarterly Statistics, Q2 2024
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2024
During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.
